{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "NEO",
  "name": "NeoGenomics, Inc.",
  "url": "https://frontierpicks.com/dossiers/NEO/",
  "json_url": "https://frontierpicks.com/dossiers/NEO.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": "LOW",
  "archetype": {
    "code": "a4",
    "n": 4
  },
  "current_thesis": "Oncology-dx turnaround accelerating — NGS +26%, PTEN IHC CDx (first FDA IHC companion dx in prostate, paired to AZ's TRUQAP) launched Jul 9, and TD Cowen $14→$19 / BofA $11→$16 on Jul 13 lifted consensus to ~$15.67, back above spot. But Q2 moved forward to Jul 28 after the close: RSI ~74 within 6% of the $15.57 high makes a fresh chase a guidance bet, not a structure bet.",
  "invalidation_trigger": "A weekly close below $13.70 forfeits the June breakout above the prior $13.74 all-time high and the $14.16 convertible conversion level, turning the move into a failed extension; secondarily, a 2026-07-28 Q2 print with NGS growth decelerating below ~20% YoY or an unchanged $797M–$803M full-year guide confirms the break.",
  "catalyst_date": null,
  "outcome": "INVALIDATED",
  "outcome_date": "2026-07-27",
  "invalidation_fired": true,
  "themes": [
    "precision-biotech-therapeutics",
    "medtech-diagnostics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "2026-07-09: PTEN IHC CDx launched — first FDA-approved IHC companion diagnostic for prostate adenocarcinoma, selects patients for AstraZeneca TRUQAP (capivasertib) via VENTANA PTEN (SP218) RxDx. 1–2 day TAT, standalone or inside NEO PanTracer Pro. Stock +3.4% on the news.",
    "2026-06-25: Carolyn Starrett (Flatiron Health CEO Apr 2021–Sep 2025) joined the board as independent director — signals a real-world-data/AI monetization leg beyond test volume.",
    "June 2026 convertible: $316M, 0.75% due 2032, conversion reference $14.16, capped-call cap $20.98 — the cap is the structural dilution ceiling.",
    "FY26 GAAP net loss is guided at $(42)-$(34)M despite Q2 2026 GAAP net income of $2M; profitability is adjusted-EBITDA-based, not GAAP.",
    "Non-clinical/pharma services is a declining line, guided down high-single-digits for FY26 after a 26% YoY drop in Q2 2026.",
    "OIG-HHS voluntary disclosure settled 2026-07-20 for $9,813,260 plus 4.250% annual interest accruing from 2026-01-16.",
    "Reporting cadence: Q3 results have historically landed in late October, with the earnings-date notice roughly three weeks ahead of the print.",
    "PTEN IHC CDx revenue depends on AstraZeneca TRUQAP (capivasertib) prescribing volume; it is a partnered, regulator-gated line."
  ],
  "body_markdown": "\nthough# NEO — NeoGenomics, Inc.\n\n## Current Thesis\nThe post-print leg is still extending, and nothing new has been added to it. NeoGenomics closed at $16.98 on 2026-08-21 — the high of the trailing 52 weeks in the adjusted daily series, with the shares up 84.0% over three months and RSI(14) at 62.0. That advance is still being paid for by one dated event: the 2026-07-28 Q2 report (revenue $201.7M, +11% YoY and about $4M above the company's own outlook; clinical revenue $187M, +14%; NGS +26% YoY at roughly one-third of clinical) and the guidance raise that came with it (FY26 revenue $802–806M from $797–803M, adjusted EBITDA $56–58M from $55–57M, FY NGS growth to mid-20s from low-20s).\n\nWhat an investor is buying is a legacy reference lab whose commodity testing funds the network while next-generation sequencing, tumour-informed MRD (RaDaR ST) and therapy-linked companion diagnostics carry growth and incremental margin. The composition of that growth is the open question and it does not get answered inside this window: Q2 average revenue per test was $515 against $461 (+11.7%) while clinical volume rose 1.9% to 363,498 tests, and Q3 volume is guided to roughly 1.5% against a high-volume, low-value contract that peaked in Q3 2025.\n\nSince the last note the flow of new information has stopped. The company's IR press-release page carried no August 2026 release when checked on 2026-08-23; the most recent items are the 2026-07-28 results, the 2026-07-20 OIG-HHS settlement and the 2026-07-09 PTEN IHC CDx launch. No sell-side target has moved since 2026-07-29. Price made the new high anyway.\n\n## Bull Case\n- **Guidance was raised, not reaffirmed (2026-07-28).** FY26 revenue $802–806M, adjusted EBITDA $56–58M, adjusted diluted EPS $0.17–0.20, with Q3 revenue growth guided near 10% and Q4 above 10%.\n- **NGS compounded 26% YoY in both Q1 and Q2 2026** and is about one-third of clinical revenue; the FY26 NGS growth target went to mid-20s from low-20s on the Q2 call. The mix line that drives gross margin runs at more than double the corporate rate.\n- **Margin arithmetic moved in the quarter.** Adjusted gross margin 48.1%, up 260bps YoY; adjusted EBITDA $14.4M, up 36% YoY on 11% revenue growth; GAAP net income $2M against a $45M net loss in Q2 2025; cash $146M at 2026-06-30.\n- **The analyst band sits above spot and has not been cut.** Per stockanalysis.com's S&P Global-sourced panel, checked 2026-08-23: average target $19.72 across 12 analysts, 6 Strong Buy / 2 Buy / 4 Hold / 0 Sell, range $16–$35. Needham went $15→$19 and Craig-Hallum $17→$19 on 2026-07-29.\n- **MRD reimbursement is the unpriced 2027 option.** A third RaDaR ST indication was submitted to MolDx in Q2; two indications are reimbursed and three pending. Management stated on 2026-07-28 that all five approved would address more than 40% of the tumour-informed MRD market, with roughly 30% of RaDaR ST orders attaching another NeoGenomics test.\n- **Regulator-gated CDx line launched 2026-07-09.** PTEN IHC CDx is the first FDA-approved immunohistochemistry companion diagnostic for prostate adenocarcinoma, selecting patients for AstraZeneca's TRUQAP (capivasertib) via the VENTANA PTEN (SP218) RxDx assay — pharma-linked volume rather than a generic panel.\n\n## Bear Case\n- **Growth is price-led.** The +11.7% AUP move did the work in Q2 while volumes grew 1.9%, and Q3 volume is guided near 1.5%. Repricing a book is a level shift; it does not repeat annually unless payer mix keeps moving.\n- **Pharma services is shrinking faster than guided.** Non-clinical revenue fell 26% YoY in Q2 and the FY26 non-clinical guide was cut to down high-single-digits from down low-to-mid-single-digits, with a return to growth targeted only in 2027.\n- **GAAP profitability is not yet structural.** FY26 net loss is guided at $(42)–$(34)M despite the $2M of GAAP net income printed in Q2 2026, and the FY26 adjusted EBITDA guide of $56–58M on $802–806M of revenue leaves little absorption for a coding or reimbursement surprise.\n- **Compliance history is live.** The voluntary disclosure to OIG-HHS settled on 2026-07-20 for $9,813,260 plus 4.250% annual interest accruing from 2026-01-16.\n- **Positioning has caught up to the sell side.** The lowest target on the 12-analyst panel is $16, below the 2026-08-21 close of $16.98, and the $19.72 average is about 16% above it. No analyst has revised since 2026-07-29 — the gap that existed on 2026-07-29 has been closed by price, not by estimates.\n- **Dilution ceiling is fixed.** The June 2026 convertible is $316M, 0.75% due 2032, conversion reference $14.16, with the capped call at $20.98.\n\n## Setup & Price Structure\nThe 2026-08-21 close of $16.98 is the highest close of the trailing year, so there is no overhead supply from the past twelve months and no measurable distance to the high. RSI(14) read 62.0 on that date against 70.5 on 2026-08-14, when the close was $15.94 — the momentum reading cooled while price advanced roughly 6.5% over the same stretch. Measured, that is what happened; the inference is that the large mid-July daily gains are rolling out of the 14-day window rather than that fresh buying accelerated. The three-month change also moderated, from 93.4% into 2026-08-14 to 84.0% into 2026-08-21, because the trailing anchor moved up.\n\nReference shelves below, all from prior structure: the mid-July pre-print high near $15.57; the $14.16 convertible conversion reference from the June 2026 issue; and the $13.74 prior all-time high that the June breakout cleared. Above the tape, $20.98 is the capped-call cap — a structural dilution ceiling, not a target.\n\n**The narrative is maturing.** Dated: the narrative-making events are behind it (2026-07-09 CDx launch, 2026-07-28 beat-and-raise, 2026-07-29 target cluster reset to $19). Since then, no company press release through 2026-08-23, no target revisions in the 25 days after 2026-07-29, and 12 analysts already covering with zero Sells. Well known, still working, with the headline flow moderating — that is the maturing profile rather than accelerating, which would require new attention arriving.\n\nCrowding and positioning observables, stated as observables: price at the 52-week high with the shares up 84.0% over three months; the panel's lowest target now sits under the last close; no earnings date inside the next 30 days, with the next print roughly nine weeks out; and $316M of convertible paper already placed in June 2026 into the advance, which is issuance into strength that has happened rather than issuance that might. No insider transaction data is cited here because none was verified for this window.\n\n## Catalyst Calendar (next 30 days)\n- **~2026-09-03 to ~2026-09-11 (est.)** — September healthcare conference season (Wells Fargo, Morgan Stanley, Baird). NeoGenomics participation was not announced as of 2026-08-23; the IR press-release page showed no August 2026 items. If it happens, it is the only chance for management commentary on AUP durability or MolDx timing before Q3.\n- **Unscheduled, any date** — MolDx coverage decisions on the three pending RaDaR ST indications. Two are reimbursed today; each decision is a discrete headline with no calendar.\n- **~2026-10-06 (est.), outside the window** — the Q3 earnings-date press release. The Q2 date was announced on 2026-07-07 for a 2026-07-28 report, so the analogous notice would land in early October.\n- **~2026-10-27 (est.), outside the window** — Q3 2026 results: the first check on the ~10% revenue growth guide, the ~1.5% volume assumption, and whether AUP holds near $515.\n\n## What Would Change Our Mind\nThe composition of growth is what breaks first if it breaks. A Q3 print showing average revenue per test below the $515 recorded in Q2 while volume growth stays near 1.5% would reframe the 2026 revenue line as a one-time repricing of the payer book rather than a mix shift, and the mid-20s NGS growth target is the specific number that would have to hold to refute that.\n\nOn the tape, a weekly close below $15.57 gives back the entire post-Q2 advance and puts price back inside the pre-print July range; the deeper structural level is the $14.16 conversion reference from the June convertible, and a weekly close under that would return the June breakout above the old $13.74 all-time high to a failed extension.\n\nTwo further conditions would matter. If the September conference season passes with no NeoGenomics appearance and no interim commentary, the name goes roughly nine weeks with no new information while sitting at its high — a saturation condition rather than a price one. And if the pending MolDx count is still three at the Q3 print, the \"more than 40% of the tumour-informed MRD market\" framing slips a further year to the right.\n\n## Correlation Notes\n- Trades with small- and mid-cap diagnostics rather than with large-cap medtech; Natera (Signatera) is the commercial reference point in tumour-informed MRD and its reported volume trend is the cleanest read-across for RaDaR ST share. Guardant, Exact Sciences and Tempus share the same reimbursement-headline sensitivity.\n- Reimbursement policy is a sector-wide factor, not an idiosyncratic one: MolDx and CMS decisions move the whole tumour-informed MRD complex on the same days.\n- With FY26 GAAP net loss guided at $(42)–$(34)M and a 2032 convertible outstanding, the equity behaves like a duration-sensitive small cap; risk appetite in XBI and IWM is the ambient driver between company events. This is an inference from the capital structure, not a measured beta.\n- Company-specific linkage: PTEN IHC CDx pull-through depends on AstraZeneca's TRUQAP prescribing, so AZ oncology commentary is a second-order input to that line.\n- The 2026-06-25 appointment of Carolyn Starrett (Flatiron Health CEO, April 2021–September 2025) to the board points at a real-world-data monetization leg, but no associated revenue line has been disclosed and none should be modelled from the appointment alone.",
  "first_seen": "2026-06-10",
  "last_analyzed": "2026-08-23T14:36:41+00:00",
  "last_synthesized": "2026-08-23",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}